


US Tardive Dyskinesia Market: Size, Trends & Forecasts (2016-2025)

December 2016



US Tardive Dyskinesia Market Report

Scope of the Report

The report entitled "US Tardive Dyskinesia Market: Size, Trends & Forecasts (2016-2025)", provides analysis of the US tardive dyskinesia market, with detailed analysis of market size and growth, penetration, market share and economic impact of the industry. The report also provides the analysis of the major drugs (both existing and in pipeline) analysis, by penetrations, by revenue, etc.

Furthermore, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall US tardive dyskinesia market has been forecasted for the years 2016-2025, taking into consideration the previous growth pattern, the growth drivers and the current and future trends.

Valeant Pharmaceuticals, Neurocrine Biosciences and Teva Pharmaceutical Industries are some of the key companies in the US tardive dyskinesia market. The company profiling of these companies has been done in the report, which includes business overview, financial overview and respective business strategies of the companies.

Company Coverage

Valeant Pharmaceuticals (Tertrabenazine)

Neurocrine Biosciences (Valbenazine)

Teva Pharmaceutical Industries (SD-809)

US Tardive Dyskinesia Market Report

Executive Summary

Psychosis is a condition described as loss of contact with reality. And the people suffering from this condition are called psychotics. Some of the signs and symptom of psychosis are: difficulty in concentrating, depressed mood, sleeping too much or not enough, anxiety, etc. The two main types of psychiatric disorder related to tardive dyskinesia are Schizophrenia and Bipolar Disorder.


Involuntary movements of face, lips, tongue, extremities and trunk, is called tardive dyskinesia. This disease is caused by regular and long term intake of dopaminergic antagonist medications/ antipsychotics as a prescription for schizophrenia and bipolar disorder. Some of the signs and symptoms of tardive dyskinesia are grimacing, tongue movements, lip smacking, lip puckering, pursing of the lips, excessive eye blinking, etc.

Tardive dyskinesia has many different treatments, including vitamin E, benzodiazepines, levodopa, reserpine, botulinum toxin, tetrabenazine, dopamine-depleting agents, and calcium channel blockers. Along with these, two new treatments are in the pipeline: Valbenazine and SD-809.

The US tardive dyskinesia market is expected to increase at a significant growth rate during the forecasted period (2016-2025). The US tardive dyskinesia market is supported by various growth drivers, such as increase in number of schizophrenia patients, rising bipolar disorder patients, etc. Yet, the market faces certain challenges, such as, increased use of atypical antipsychotics, under-diagnosed market, side effects of drugs, etc.


US Tardive Dyskinesia Market Overview

US Tardive Dyskinesia Market by Number of Patients; 2016-2020 ('000)




The number of patients suffering and diagnosed from tardive dyskinesia disease is estimated to be thousand in 2016. However, due to unusual pathology Total tardive dyskinesia patients in the US in 2017, is expected to be comprised of ...% of patients and% of patients, making total tardive dyskinesia patients estimate to reach thousand in 2017. It is assumed that out of total tardive dyskinesia patients, ...% patients have moderate to severe tardive dyskinesia, which make them....

US Tardive Dyskinesia Market Number of Patients by Segments; 2017




US Tardive Dyskinesia Market Number of Patients by Severity; 2016-2025 ('000)




US Tardive Dyskinesia Drugs Market Overview

US Valbenazine Market by Penetration; 2017-2025



The penetration of Valbenazine in the US is expected to be 28.28% in 2017, which is expected to increase to 33.33% in 2018 and 38.39% in 2019. It is assumed that Valbenazine would be launched in the US in 2017 and in Japan in 2018, with no other countries. Also, it is assumed that there will be 91.87% compliance rate in 2025. The number of patients on Valbenazine is estimated to be 2828 in 2017 and 91870 in 2025.


US Valbenazine Market by Number of Patients; 2017-2025



US Tardive Dyskinesia Drugs Market Overview


US SD-809 Market by Penetration; 2019-2025

Percentage, %



US Tetrabenazine Market (For TD) by Penetration; 2017-2025

Percentage, %



SD-809 has initially been filed for use in....., with the NDA for tardive dyskinesia expected The penetration of SD-809 for tardive dyskinesia to be ...% in 2019 and the same is expected to increase to ...% in 2025. The penetration for Tetrabenazine for the treatment of tardive dyskinesia is estimated to decrease in coming years due to introduction.... treatment...